



THOMSON PHARMA 9.2 新功能概览

2010年2月



THOMSON REUTERS

THOMSON PHARMA 2010年2月升级

- 全面提升Thomson Pharma的稳定性和性能，特别是检索功能
- 主要包括以下内容的改进：
 - 检索功能的改进
 - 自动完成功能的改进
 - 临床试验模块的增强

检索功能的改进(1)

- 大大减少长时间运行检索时返回0结果（**Zero results**）错误信息的次数（例如，用户应该得到检索结果但是却只得到0结果的信息）
 - 药物检索和公司检索进一步优化，目前支持左截断检索
 - 当**Quick Search**只包含1个字符和1个通配符时，自动出现以下新的提示信息

Any Quick Search term containing a wildcard must contain at least three alphanumeric characters. Please refine your search.

检索功能的改进(2)


- 化学结构检索，新增查看检索式功能，在检索式运行之前即可避免检索结果过于广泛，节省时间

旧的化学结构检索流程



检索功能的改进(3)

新的化学结构检索流程



检索功能的改进(4)

- 修订0结果提示信息（Zero results）的内容，帮助用户理解为何出现检索结果为0的情况。
 - 旧版显示信息

Zero results! No reports matching your query were found. Please amend your search.

- 新版显示信息

Sorry, your search did not match any results. Make sure:

- Terms entered are spelled correctly
- Terms are being searched using the correct field or category (eg Quick Search for a drug with “Company name” selected would find zero results)
- Terms are being searched in the right place in Thomson Pharma (try using Search Centre)

The data searched may not exist in Thomson Pharma, or you may need to try alternative keywords. Using autocomplete suggestions (where available) can help ensure you retrieve valid results. For more assistance on searching Thomson Pharma, please refer to Help.

检索功能的改进(5)

- 引入新的系统信息，处理由于技术原因的失败检索
 - 显示以下信息，取代Java和Javascript错误信息，超时或白屏的提示信息
 - 用户可以从提示信息获悉，检索失败是因为技术原因
 - 提示信息将给出ID代码，便于用户转发给技术支持，快速调查和识别问题原因

Your search could not be completed at this time, please try again later. If the problem persists please contact Technical Support and quote the following search code: 3456771

检索功能的改进(6)

- 在Quick Search中修订检索类型的次序
 - 检索类型的次序以用量为依据（例如：使用频率）
 - 用户常常输入一个公司名称，却选择检索类型为化合物名称Compound name
 - 可能因为化合物名称（Compound name）在列表的上方
 - 化合物Compound 和公司Company常常被母语非英语的用户所混淆，尤其是它们在列表中的位置如此接近
 - 混淆化合物和公司检索类型是返回0结果Zero results信息最重要的原因之一

检索功能的改进(7)

旧版顺序	新版顺序
Drug name	Drug name
Compound name	Company name
Patent number	Patent number
Company name	Target
Lit & News Title	Therapy Area
Author/Inventor	Action
Target	Technology
Therapy Area	Compound name
Action	Lit & News Title
Technology	Author/Inventor

检索功能的改进(8)

- 检索结果页面新增内容 (日期和时间标识每日更新)

Summary

Content updates: **05-JAN-2010 01:01 EST**

Select all [Show Checked](#)

[APD-310](#) **DR**
Updated on 30-DEC-2009. Originator: Acacia Pharma Ltd . Highest Dev
Status: No Development Reported.

[armodafinil](#) **DR**
Updated on 30-DEC-2009. Originator: Cephalon Inc . Highest Dev
Status: Launched.

[galantamine](#) **DR**
Updated on 30-DEC-2009. Originator: Sanochemia Pharmazeutika AG .
Highest Dev Status: Launched.

自动完成功能的改进

- 自动完成建议条数从8个增加至16个
- 增加自动完成建议框的宽度，显示更加清晰


The screenshot shows a search interface with a search bar containing the text 'cel'. A dropdown menu is open, displaying 16 suggestions. The suggestions are as follows:

Suggestion	Matched Part
celastrol (cancer), Schering-P...	cel
celastrol methyl ester	(celastrol (cancer), Schering-P...)
celecoxib	(celecoxib (injectable, pain), ...)
celecoxib	(celecoxib (sustained release i...)
celecoxib	
celecoxib (injectable, pain), ...	
celecoxib (sustained release i...	
celecoxib FAP	(celecoxib)
celecoxib derivatives (cancer)...	(AR-12)
celgosivir	
celgosivir hydrochloride	(celgosivir)
celikalim	(celikalim derivatives (urge ur...)
celikalim derivatives (urge ur...	
celiprolol	
celiprolol hydrochloride	(celiprolol)
celivarone	



客户需求建议

- 增加报告之间相互转换的可选项
 - Company ↔ Patent
 - Drug ↔ Patent
 - Drug ↔ Deal
- 交易报告Deal Report过滤饼图包括Asia-Asia过滤选项功能



临床试验模块的增强(1)

- 临床试验页面，“Trials added by week”图示的标题有所变化
 - 避免所包含临床试验阶段的混淆
 - 新的标题为“Phase 1, 2 and 3 Trials Added by Week”

临床试验模块的增强(2)

- 修订Outcomes measures检索
 - 旧版中，只有在用户完全了解数据库中outcome measures描述的研发阶段，才能够返回检索结果
 - 用户很难了解或猜测正确的研发阶段
 - 新版中，用户可以在Protocols Form Search通过执行子检索直接检索到临床试验outcome measures内容
 - 例: 甲状腺球蛋白Thyroglobulin水平通常在癌症药物临床试验中作为测量指标，然而旧版中，用户在Outcome Measures字段输入“thyroglobulin”却没有检索结果

临床试验模块的增强(3)

- 修订临床试验报告的结果评估 **Outcomes measures**
 - 与 **Outcomes measures** 相关联的时间数据显示在专门的一列（如果有内容提供）

Outcomes measures		
Primary outcome measures	<ul style="list-style-type: none">■ Radiographical response rate as assessed by RECIST criteria■ Progression-free survival rate	<ul style="list-style-type: none">After completion of 8 weeks of study therapy6-months
Secondary outcome measures	<ul style="list-style-type: none">■ Safety and toxicity profile, in terms of adverse events, laboratory data, and vital sign data■ Biological effect of aflibercept on fludeoxyglucose F 18 avidity■ Correlation of thyroglobulin concentration with radiographic response■ Correlation of thyroglobulin concentration with progression-free survival■ Correlation of pre-treatment serum aflibercept concentration with clinical outcomes after therapy■ Pharmacokinetics■ Development of aflibercept antibodies	<ul style="list-style-type: none">At 8 weeksAt 8 weeksAt 6 monthsAt 6 monthsAt 6 monthsAt 6 months

临床试验模块的增强(4)

- 在临床试验结果报告显示作用机制
 - Outcomes reports新增字段，显示干涉研究相关联的作用机制

OR Results of a phase I study to determine the...

OVERVIEW	TRIAL SITES	REGIMEN DETAILS	OUTCOMES	ADVERSE EVENTS	SOURCES
----------	-------------	-----------------	----------	----------------	---------

SUMMARY INTERVENTIONS SPONSORS STUDY DESIGN ELIGIBILITY

SUMMARY i

Brief title	Results of a phase I study to determine the safety and tolerability of galantamine in Alzheimer patients as well as healthy subjects
Condition Studied	Chronic fatigue syndrome,Alzheimers disease,Arthritis
Actions Studied	Acetylcholinesterase inhibitor;Neuroprotectant
Study Phase	Phase 1 Clinical
Protocol Report	A phase I study to determine the safety and tolerability of galantamine in Alzheimer patients as well as healthy subjects

临床试验模块的增强(5)

- 新增 “Reason Trial Terminated” 字段
 - 临床试验终止的原因会显示在 Protocol Report 中(在 Status内容栏中)

STATUS

Study Phase	Phase 2 Clinical
Overall Recruitment Status	Terminated
Reason Trial Terminated	Study accrual was terminated because of poor tolerance of valproic acid and inability to consistently titrate the dose of valproic acid to maintain the total valproic acid blood level of < 50 microg/l [1064923].
Study start date	22-APR-2005